araag2/HINT huggingface dataset:
Clinical trial NCT02031081 (phase 2/phase 3, status: completed)
Conditions: gastroparesis, diabetes mellitus
ICD codes: K31.84, P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: prucalopride, placebo
SMILES: COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age of 18-64 years

          -  Existing clinical diagnosis of gastroparesis for at least one year as judged by the
             study gastroenterologist based on past medical history, clinical symptoms

          -  Sufficiently symptomatic at time of proposed study (Minimum baseline postprandial
             satiety/fullness subscale of the Gastroparesis Cardinal Symptoms Index (GCSI) score of
             1.5 or higher)

          -  Delayed gastric emptying (>10% retention at 4 hours) on standard solid meal
             scintigraphic emptying study within the previous year

          -  Normal upper endoscopy (with the exception of small bezoars) since the onset of
             symptoms

          -  If female of childbearing potential, a negative urine pregnancy test administered
             between consent and screening appointments

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  Clinical evidence (including physical exam and/or ECG) of significant cardiovascular,
             respiratory, renal, hepatic, gastrointestinal, hematological, neurological,
             psychiatric or other disease that may interfere with the objectives of the study
             and/or pose safety concerns, including pregnancy or breastfeeding.

          -  Study entry ECG showing second or third degree heart block, left bundle branch block
             (LBBB) or acute ischemic changes

          -  Blood electrolytes (Na, K, CL) measured within past 6 months outside of normal
             reference ranges (except during an acute gastroparesis flare-up)

          -  Use of narcotics or promotility agents which cannot be stopped prior to study entry.

          -  Use of tricyclic antidepressants (at doses exceeding 25 mg/day) and/or macrolide
             antibiotics. (Stable doses of SSRI/SNRI antidepressants and/or non-macrolide
             antibiotics are permitted)

          -  Laxative use that cannot be stopped prior to the start of the study

          -  Participated in clinical trial with motility agents within past 30 days

          -  History of gastrointestinal surgery excepting appendectomy and/or cholecystectomy in
             the past, or any other major surgeries within 3 months

          -  Estimated GFR<30 measured within past 6 months.

          -  History of cardiovascular disorder including myocardial infarction, pacemaker or
             implanted defibrillator, or history of life-threatening arrhythmia
Clinical trial NCT02031458 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: atezolizumab
SMILES: CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult participants greater than or equal to 18 years of age

          -  Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC

          -  Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens

          -  PD-L1-positive tumor status as determined by an immunohistochemistry (IHC) assay based
             on PD-L1 expression on tumor infiltrating immune cells and/or tumor cells performed by
             a central laboratory

          -  Measurable disease, as defined by RECIST version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3
             weeks prior to initiation of study treatment; the following exception are allowed:

        Hormone-replacement therapy or oral contraceptives tyrosine-kinase inhibitors (TKIs)
        approved for treatment of NSCLC discontinued >7 days prior to Cycle 1, Day 1

          -  Central nervous system (CNS) disease, including treated brain metastases

          -  Malignancies other than NSCLC within 5 years prior to randomization, with the
             exception of those with negligible risk of metastases or death and treated with
             expected curative outcome

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis (including pneumonia), drug-induced
             pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening CT
             scan. History of radiation pneumonitis in the radiation field (fibrosis) id permitted

          -  Active hepatitis B or hepatitis C

          -  Human Immunodeficiency virus (HIV) positive

          -  Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic
             antibody or pathway-targeting agents
Clinical trial NCT02033278 (phase 2, status: terminated)
Conditions: idiopathic dilated cardiomyopathy
ICD codes: Q93.81, B33.4, A36.81, A50.54, A52.00, A52.09, B33.24
Drugs: infusion of autologous mononuclear bone marrow cells, placebo infusion
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    low recruitment rate, bibliographic evidence of lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients of both sexes and ages between 18 and 70 years.

          2. Patients diagnosed with dilated cardiomyopathy established by echocardiography.

          3. Minimum evolution since diagnosis of 6 months.

          4. Absence of coronary injury tested with multislice CT and/or hemodynamic study
             performed after study entry, or within the previous 36 months (or before in specific
             low risk clinical profiles) if no angina symptomatology is present.

          5. Patients receiving optimized medical therapy for at least 6 months prior to enrollment
             (individually adjusted according to functional status).

          6. Ejection fraction of the left ventricle <40% or ejection fraction of the left
             ventricle 40% -50% if left ventricular tele-diastolic volume is > 110 ml/m2.

          7. Presence of sinus rhythm.

          8. Writen informed consent for participation in the trial.

          9. Normal laboratory parameters, defined by: Leukocytes ≥ 3000; Neutrophils ≥ 1500;
             Platelets ≥ 100,000; Aspartate aminotransferase / Alanine aminotransferase ≤ 2.5
             standard range institution; Creatinine ≤ 2.5 mg / dL; Haemoglobin > 9 g/dL

         10. Women of childbearing potential must have negative results on a pregnancy test and
             agree to use medically approved methods of contraception thoughout follow up.

        Exclusion Criteria:

          1. Secondary Dilated cardiomyopathy.

          2. Recent history of myocarditis (< 6 months prior to study entry).

          3. Patients amenable to receive cardiac resynchronization therapy

          4. Patients in active waiting list for heart transplantation.

          5. Coexistence of other serious systemic diseases.

          6. Coexistence of any type of blood disease

          7. Pregnant or breastfeeding women; or women of childbearing potential not comminting to
             use effective contraception.

          8. Patients who are currently participating, or have completed their participation in a
             clinical trial within the last 3 months. Patients who have participated in any
             advanced therapies clinical trial any time previously.

          9. Patients with malignant or pre-malignant tumors.

         10. Positive serology for hepatitis B virus, hepatitis C virus or human immunodeficiency
             virus.

         11. Use of any protocolo prohibited medication. A wash-out period of 2 months can be
             considered for inclusion in the trial.
Clinical trial NCT02038179 (phase 2/phase 3, status: completed)
Conditions: pre-hypertension, jnc 7 stage i hypertension
ICD codes: O11.1, O11.2, O11.3, O11.4, O11.9, O11.5, O10.02, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: allopurinol, placebo
SMILES: O=C1N=CN=C2NNC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Pre-hypertension or stage I hypertension, defined as the following after the mean of
             two clinic measurements:

          -  Systolic blood pressure (SBP) ≥ 120 and <160 or;

          -  Diastolic blood pressure (DBP) ≥ 80 and < 100

          -  Serum urate ≥ 5.0 mg/dL for men or ≥ 4.0 mg/dL for women

          -  Age 18-40

        Exclusion Criteria:

          -  Any current pharmacological treatment for hypertension, including diuretics (calcium
             channel blockers at stable doses were later allowed)

          -  Estimated glomerular filtration rate < 60 mL/min/1.73m2

          -  Current use of any urate-lowering therapy or statins

          -  Prior diagnosis of gout or past use of urate-lowering therapy for gout

          -  Prior diagnosis of diabetes

          -  Pregnancy, or recent delivery or last trimester pregnancy loss more recent than 3
             months

          -  Active smokers

          -  Immune-suppressed individuals including transplant recipients or current use of
             azathioprine.

          -  Leucopenia with absolute white cell count < 3000 /mL, anemia with hemoglobin < 12
             g/dL, or thrombocytopenia with platelet count < 150,000/mL

          -  Individuals of Han Chinese or Thai descent with HLAB5801 genetic phenotype

          -  Serious medical condition that at investigator's judgment precludes utilization of a
             fixed dose of allopurinol
Clinical trial NCT02038816 (phase 2, status: terminated)
Conditions: myelodysplastic syndromes
ICD codes: D46.9, D46.C, D46.Z
Drugs: deferasirox + azacitidine, azacitidine
SMILES: OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Reason stopped: 
    accrual too slow, insufficient patients
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adults >18 yrs of age

          -  WHO defined MDS with Higher risk MDS (IPSS int-2/high)

          -  Azacitidine X at least 6 cycles with no hematologic improvement/no disease progression
             as per IWG 2006 criteria

          -  Ferritin >500 µg/L

          -  If transfusion independent, must have Hb <110 g/L OR Neutrophils < 1,000/mL OR
             Platelets < 100,000/mL

          -  ECOG ≤2

          -  CrCl >40 ml/min

        Exclusion Criteria:

          -  Increased ALT (>300 U/L)

          -  Uncontrolled infection

          -  HIV+

          -  Pregnant or breast-feeding

          -  Previous and concurrent iron chelation

          -  Concurrent use of hematopoietic growth factors including erythropoietin, darbepoietin
             and granulocyte colony stimulating factor

          -  Concurrent use of other disease modifying agents including cytotoxic chemotherapy,
             histone deacetylase inhibitors, other hypomethylating agents or lenalidomide
Clinical trial NCT02039947 (phase 2, status: completed)
Conditions: melanoma and brain metastases
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: dabrafenib, trametinib
SMILES: CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1, CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  ECOG Performance Status range of 0-2

          -  Histologically confirmed cutaneous metastatic melanoma of V600 E, K, D or R.

          -  May be systemic naïve or received up to two previous systemic treatment regimens for
             metastatic melanoma.

          -  Must be able to undergo MRI and have at least one measurable intracranial lesion for
             which specific criteria have to be met.

        Exclusion Criteria:

          -  Prior treatment with any BRAF inhibitor or any mitogen-activated protein/extracellular
             signal-regulated kinase inhibitor.

          -  Anti-cancer therapy or investigational anti-cancer therapy or chemotherapy without
             delayed toxicity within treatment specific timeframe.

          -  Treatment with stereotactic radiosurgery or treatment with whole-brain radiation
             within treatment specific timeframe.

          -  Any presence of leptomeningeal disease or any parenchymal brain metastasis

          -  History of another malignancy, some exceptions may apply.

          -  A history or evidence of cardiovascular risk- specific criteria have to be met

          -  A history or current evidence/risk of retinal vein occlusion or retinal pigment
             epithelial detachment - specific criteria have to be met.
Clinical trial NCT02040623 (phase 2, status: completed)
Conditions: chronic graft-versus-host disease
ICD codes: D89.811, D89.812
Drugs: r348 ophthalmic solution, 0.2%, r348 ophthalmic solution, 0.5%
SMILES: CCC(=O)NS(=O)(=O)C1=CC(NC2=NC=C(F)C(NC3=CC=C(OCC#C)C=C3)=N2)=CC=C1C, CCC(=O)NS(=O)(=O)C1=CC(NC2=NC=C(F)C(NC3=CC=C(OCC#C)C=C3)=N2)=CC=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Received an Allogeneic hematologic stem cell transplantation at least 3 months prior.

          -  Subjects with post Allogeneic hematologic stem cell transplantation onset or worsening
             of dry eye symptoms for at least 1 month prior.

          -  Use of over-the-counter and/or prescription eye drops for dry eye symptoms within 1
             month.

          -  Corneal fluorescein staining score of ≥ 2 in 1 region and ≥ 1 in at least 1 other
             region.

          -  Total lissamine green conjunctival staining score (according to a modified National
             Eye Institute grading system) of ≥ 2.

        Exclusion Criteria:

          -  Clinically unstable Graft versus Host Disease (requiring a change in immunosuppressive
             regimen), medical condition, or laboratory abnormality

          -  Used topical ophthalmic cyclosporine within 45 days.

          -  Used any topical ophthalmic steroid within 2 weeks.

          -  Used autologous serum eye drops within 2 weeks.
Clinical trial NCT02042534 (phase 2, status: completed)
Conditions: ischemic stroke, transient ischemic attack
ICD codes: I25.5, H47.013, H93.013, G45.9, H47.011, H47.012, H47.019, G45.9, Z86.73, G45.8
Drugs: rivaroxaban, warfarin
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, S1SSSSSSS1
Eligibility criteria:

        Inclusion Criteria: All of below

          -  Acute ischemic stroke or TIA presumed to be cardioembolic origin (within 5 days from
             stroke onset) with mild severity: infarct size on DWI less than 1/3 of MCA territory,
             1/2 of ACA territory, 1/2 of PCA territory, and 1/2 of one cerebellar hemisphere

          -  Atrial fibrillation including paroxysmal atrial fibrillation: atrial fibrillation must
             be documented by ECG evidence (e.g., 12-lead ECG, rhythm strip, Holter, pacemaker
             interrogation) within 30 days before randomization. This could be obtained from a
             notation in the subject's record (e.g., medical chart, hospital discharge summary).

          -  Age ≥19 years

          -  Informed consent

        Exclusion Criteria: Any of below

          -  Chronic renal failure (GFR less than 30ml/min) or severe hepatic impairment

          -  Significant hemorrhagic transformation (parenchymal hematoma type I or II by the ECASS
             definition)

          -  Stroke mechanism of presumed small vessel occlusion: single small subcortical infarct
             in the perforating artery territory

          -  Large hemispheric or cerebellar infarction; larger than 1/3 of MCA territory, 1/2 of
             ACA territory, 1/2 of PCA territory, and 1/2 of one cerebellar hemisphere

          -  Mechanical valve requiring warfarin therapy

          -  Active internal bleeding

          -  Prior history of symptomatic intracranial bleeding

             : patients with asymptomatic bleedings or microbleedings on MRI are eligible for
             inclusion

          -  Major surgery or major trauma within 30 days that might be associated with increased
             bleeding risk

          -  Clinically significant gastrointestinal bleeding within 6 months

          -  Intravenous tissue plasminogen activator use or mechanical embolectomy within 48 hours
             plus 'significant hemorrhagic transformation as described above (exclusion criteria
             2)' or 'large hemispheric infarction or cerebellar infarction as described above
             (exclusion criteria 4)'

             : patients achieving successful reperfusion without hemorrhage nor large infarction
             are eligible for enrollment

          -  Severe anemia: hemoglobin <10 g/dL

          -  Bleeding diathesis; thrombocytopenia (<90,000/µL, prolonged PT (INR>1.7)

          -  Sustained uncontrolled hypertension: SBP >180 mmHg or DBP >100 mmHg

          -  Severe devastating illness, such terminal cancer, hepatic failure; therefore, the
             participants have a life expectancy less than 6 months.

          -  Planned invasive procedure with potential for uncontrolled bleeding, including major
             surgery
Clinical trial NCT02044146 (phase 2/phase 3, status: completed)
Conditions: acute coronary syndrome, percutaneous coronary intervention
ICD codes: I24.0, Y35.312S, Y35.313S, Y35.412S, Y35.413S, Y35.812S, Y35.813S, Y35.92XS
Drugs: ticagrelor, prasugrel, clopidogrel
SMILES: CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients: age >18 yrs, < 75yrs

             -> 60 kg ( since March 2015 age >75 and < 60 kg eligible - but prasugrel reduced to
             5mg daily if randomized to personalized therapy arm)

          -  NSTEMI undergoing PCI will be eligible

        Exclusion Criteria:

        - Patients will be excluded if they have: i) a contra-indication for clopidogrel or
        prasugrel or ticagrelor (as per monograph), ii) have an intolerance to aspirin, iii) have
        absolute requirement for ticagrelor or prasugrel (e.g. stent thrombosis, allergic reaction
        to clopidogrel), iv) requirement for anti-coagulation treatment, v) a history of stroke,
        TIA or intracranial hemorrhage , vi) a platelet count < 100,000/μl, vii) a known bleeding
        diathesis, viii) hematocrit <30% or >52%, ix) severe liver dysfunction, x) renal
        insufficiency (creatinine clearance < 30ml/min), xi) adjuvant therapy with a glycoprotein
        IIbIIIa inhibitor.
Clinical trial NCT02044874 (phase 2, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: apd356-lorcaserin hydrochloride, placebo
SMILES: C[C@H]1CNCCC2=CC=C(Cl)C=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males or females aged 18-65 years, inclusive

          2. ≥10 cigarettes per day with no period of abstinence longer than 3 months in the past
             year and who are motivated to quit smoking

          3. Able to give signed informed consent

          4. Eligible female patients will be:

               1. non-pregnant

               2. non-lactating

               3. agree to use an acceptable method of effective contraception during the study

          5. Eligible male patients agree to use contraception when sexually active with a female
             partner who is not using an acceptable method of birth control

          6. Body weight of ≥50 kg (110 pounds), inclusive

          7. Considered to be in stable health in the opinion of the investigator

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from the study.

          1. Prior or current use of lorcaserin HCl

          2. Prior participation in any study of a nicotine vaccination

          3. Use of other therapies for smoking cessation is not allowed within 3 months of
             screening through study exit

          4. Use of tobacco products other than cigarettes

          5. Prior use of fenfluramine or dexfenfluramine

          6. Serious or unstable medical condition or clinically significant new illness within the
             6 months prior to screening

          7. Previous participation in any clinical study within 6 weeks prior to the screening
             visit

          8. History of severe allergies, severe drug or excipient allergy or hypersensitivity

          9. History of significant cardiovascular condition

         10. History of other significant medical conditions

         11. Significant risk of suicide

         12. Anticipated use of any agents that are associated with valvulopathy and/or pulmonary
             hypertension

         13. Positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis
             C

         14. Recent history of alcohol or drug/solvent abuse

         15. Concurrent participation in the study by more than one member of the same household

         16. Not suitable to participate in the study in the opinion of the investigator